RxDoctor Payments Data

Kathleen Malinis, NP

Nurse Practitioner · Elgin, ILNPI 1124544978

Payments from drug & device makers

$1,408in general payments, 2019–2025

Across 59 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$347
  • Dexcom, Inc.$247
  • Lilly USA, LLC$207
  • Medtronic$125
  • Novo Nordisk$122
  • AbbVie$109
  • plus $251 from 6 others

What the payments were for

  • Food & beverage$1,408100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,408 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$67,296
Medicare patients
303
Services billed
1,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$189,069
JardianceEmpagliflozin30$41,272
Fiasp FlextouchInsulin Aspart (Niacinamide)14$34,868
Tresiba Flextouch U-100Insulin Degludec20$34,456
TrulicityDulaglutide19$34,050
MounjaroTirzepatide24$31,861
FarxigaDapagliflozin Propanediol27$27,759
RybelsusSemaglutide15$22,620
Tresiba Flextouch U-200Insulin Degludec12$16,622
Humalog Kwikpen U-100Insulin Lispro29$15,038
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$14,226
Lantus SolostarInsulin Glargine,hum.Rec.Anlog80$13,766
Novolog FlexpenInsulin Aspart20$8,696
Insulin Lispro Kwikpen U-100Insulin Lispro13$7,230
Nano 2nd Gen Pen NeedlePen Needle, Diabetic36$6,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$122$216,680154 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$207$70,90568 claims
AbbVieSynthroid$109$95312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →